Skip to main content

Advertisement

Log in

Diagnosis and treatment of multifocal motor neuropathy

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Multifocal motor neuropathy (MMN) is a unique disease mimicking motor neuron disease, but it is treatable with intravenous immunoglobulins. Anti-GM1 IgM antibody titers are not sensitive enough to predict the outcome. Electrodiagnosis is essential for the diagnosis of MMN. Conduction block has been suggested as the best diagnostic marker, but it is not found in all treatable cases. Activity-dependent conduction changes, as revealed by comparing conduction before and after maximal voluntary contraction of the muscle, are a convenient and promising tool. Treatment options include various immunosuppressants (including cyclophosphamide), but there has not been ample evidence in favor of any of these agents in randomized controlled trials. Intravenous immunoglobulins remain the mainstay for treating MMN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Roth G, Rohr J, Magistris MR, Ochsner F: Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia. Eur Neurol 1986, 25:416–423.

    Article  PubMed  CAS  Google Scholar 

  2. Parry GJ, Clarke S: Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988, 11:103–107.

    Article  PubMed  CAS  Google Scholar 

  3. Pestronk A, Cornblath DR, Ilyas AA, et al.: A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988, 24:73–78.

    Article  PubMed  CAS  Google Scholar 

  4. Kaji R, Shibasaki H, Kimura J: Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology 1992, 42:506–509.

    PubMed  CAS  Google Scholar 

  5. Kaji R, Oka N, Tsuji T, et al.: Pathological findings at the site of conduction block in multifocal motor neuropathy. Ann Neurol 1993, 33:152–158.

    Article  PubMed  CAS  Google Scholar 

  6. Kaji R, Bostock H, Kohara N, et al.: Activity-dependent conduction block in multifocal motor neuropathy. Brain 2000, 123:1602–1611.

    Article  PubMed  Google Scholar 

  7. Slee M, Selvan A, Donaghy M: Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007, 69:1680–1687.

    Article  PubMed  Google Scholar 

  8. Donaghy M, Mills KR, Boniface SJ, et al.: Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994, 57:778–783.

    Article  PubMed  CAS  Google Scholar 

  9. Kiernan MC, Guglielmi JM, Kaji R, et al.: Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002, 125:664–675.

    Article  PubMed  Google Scholar 

  10. Kaji R: Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 2003, 27:285–296.

    Article  PubMed  Google Scholar 

  11. Kusunoki S, Mizutani K, Oka N, et al.: Chronic motor axonal neuropathy associated with antibodies monospecific for N-acetylgalactosaminyl GD1a. Muscle Nerve 2000, 23:702–706.

    Article  PubMed  Google Scholar 

  12. Nodera H, Bostock H, Izumi Y, et al.: Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test. Neurology 2006, 67:280–287.

    Article  PubMed  CAS  Google Scholar 

  13. Azulay JP, Blin O, Pouget J, et al.: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994, 44:429–432.

    PubMed  CAS  Google Scholar 

  14. Kubori T, Mezaki T, Kaji R, et al.: [The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy] [Japanese]. No To Shinkei 1999, 51:127–135.

    PubMed  CAS  Google Scholar 

  15. van Schaik IN, Bouche P, Illa I, et al.: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 2006, 13:802–808.

    Article  PubMed  Google Scholar 

  16. Umapathi T, Hughes R: Mycophenolate in treatmentresistant inflammatory neuropathies. Eur J Neurol 2002, 9:683–685.

    Article  PubMed  CAS  Google Scholar 

  17. Piepers S, Van den Berg-Vos R, Van der Pol WL, et al.: Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain 2007, 130:2004–2010.

    Article  PubMed  Google Scholar 

  18. Ruegg SJ, Fuhr P, Steck AJ: Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004, 63:2178–2179.

    PubMed  Google Scholar 

  19. Gorson KC, Natarajan N, Ropper AH, Weinstein R: Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007, 35:66–69.

    Article  PubMed  CAS  Google Scholar 

  20. Brannagan TH 3rd, Alaedini A, Gladstone DE: High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy. Muscle Nerve 2006, 34:246–250.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ryuji Kaji.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaji, R. Diagnosis and treatment of multifocal motor neuropathy. Curr Treat Options Neurol 10, 103–107 (2008). https://doi.org/10.1007/s11940-008-0012-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-008-0012-2

Keywords

Navigation